About this trial
UPRIGHT-HTM will compare risk stratification, treatment efficiency and health economic outcomes of a diagnostic approach based on home blood pressure telemonitoring combined with urinary proteomic profiling with home blood pressure telemonitoring alone
Eligibility criteria
Qualifiers
Patients must have at least three additional guideline-defined risk factors, preferably including hypertension, type 2 diabetes mellitus (T2DM), or both;
Patients should be willing patients to engage for the duration of the study in home blood pressure telemonitoring (1 reading per day);
Patients must have an email address and internet access via smartphone, tablet, or laptop or desktop computer;
Patients should comply with the study protocol during the run-in phase.
Disqualifiers
Type 1 diabetes mellitus;
Absence of a practicable echocardiographic window;
Previous or concurrent severe cardiovascular or non-cardiovascular disease;
Cancer within 5 years of enrolment;
Trial design
Treatments tested in this trial
- In-vitro urinary diagnostic test
Treatment groups
Sponsors and collaborators
KU Leuven
Lead sponsor
Alliance for the Promotion of Preventive Medicine
Collaborator